RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 17 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 18

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  2. Study siteAffiliated Cancer Hospital of Guizhou Medical University贵州医科大学附属肿瘤医院GuiyangHospital page
  3. Study siteDongguan People's Hospital东莞市人民医院DongguanHospital page
  4. Study siteEye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院ShanghaiHospital page
  5. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  6. Study siteFirst People's Hospital of Foshan佛山市第一人民医院FoshanHospital page
  7. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  8. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  9. Study siteGuangzhou Panyu Central Hospital广州医科大学附属番禺中心医院GuangzhouHospital page
  10. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  11. Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
  12. Study siteRenmin Hospital of Wuhan University武汉大学人民医院WuhanHospital page
  13. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  14. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  15. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  16. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  17. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  18. Study siteZhongshan City People's Hospital中山市人民医院ZhongshanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06749899, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 65 years; sex: all

    Registered eligibility fields

  2. Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma according to WHO criteria.

    Inclusion criterion 2

  3. Tumor staged as T4N1 and T1-4N2-3 (AJCC 9th)

    Inclusion criterion 3

    Stage II: T1-3N2

    Inclusion criterion 4

    Stage III: T1-4N3, T4N1-2

    Inclusion criterion 5

  4. Women of childbearing potential (WOCBP) must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug (e.g., condoms, physician-guided regular use of oral contraceptives).

    Inclusion criterion 18

  5. Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

    Inclusion criterion 9

    Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×ULN

    Inclusion criterion 10

    Alkaline phosphatase ≤ 2.5 × ULN

    Inclusion criterion 11

  6. Positive for hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA >1×103 copies/mL, positive for anti-hepatitis C virus (HCV) antibody , positive for anti-hepatitis C virus (HCV) antibody

    Exclusion criterion 1

    Positive for anti-HIV antibody or diagnosed with acquired immunodeficiency syndrome (AIDS).

    Exclusion criterion 2

  7. Pregnant or breastfeeding women (pregnancy testing should be considered for women of childbearing potential with active sexual life)

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06749899, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria

  • Age ≥18 and ≤65 years
  • Patients with histologically confirmed non-keratinizing nasopharyngeal carcinoma according to WHO criteria.
  • Tumor staged as T4N1 and T1-4N2-3 (AJCC 9th)
  • Stage II: T1-3N2
  • Stage III: T1-4N3, T4N1-2
  • Eastern Cooperative Oncology Group performance score of 0-11.
  • Adequate marrow function: white blood cell count > 4 × 10⁹/Lhemoglobin >90g/L and platelet count >100×10⁹/L
  • Adequate hepatic and renal function:
  • Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
  • Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×ULN
  • Alkaline phosphatase ≤ 2.5 × ULN
  • clearance rate ≥ 60 ml/min
  • Other laboratory and clinical criteria
  • Normal thyroid function, serum amylase and lipase, pituitary hormone levels, inflammatory markers, cardiac enzyme tests and electrocardiogram (ECG)
  • For patients aged >50 years with a history of smoking, normal pulmonary function test (PFT) results are required
  • For patients with abnormal ECG findings or a prior history of cardiovascular disease (not meeting any exclusion criteria listed in Item 8), additional assessments including myocardial function evaluation and cardiac ultrasound (echocardiography) must be performed, with results within normal limits
  • Patients must be informed of the investigational nature of this study and give written informed consent, and be willing and able to comply with the study schedule, including follow-up visits, treatment procedures, laboratory testing, and other protocol-related requirements.
  • Women of childbearing potential (WOCBP) must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug (e.g., condoms, physician-guided regular use of oral contraceptives).

Exclusion Criteria

  • Positive for hepatitis B surface antigen (HBsAg) with hepatitis B virus DNA >1×103 copies/mL, positive for anti-hepatitis C virus (HCV) antibody , positive for anti-hepatitis C virus (HCV) antibody
  • Positive for anti-HIV antibody or diagnosed with acquired immunodeficiency syndrome (AIDS).
  • Active pulmonary tuberculosis: Patients with a history of active tuberculosis within the past year should be excluded regardless of treatment status. Patients with a history of active pulmonary tuberculosis more than one year prior should also be excluded, unless they received confirmed and regular anti-tuberculosis treatment.
  • Active, known, or suspected autoimmune diseases, including but not limited to uveitis, colitis, hepatitis, hypophysitis, nephritis, vasculitis, systemic lupus erythematosus, hyperthyroidism, hypothyroidism, and asthma requiring bronchodilators. Type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) are allowed.
  • Thymic epithelial tumors (TETs), including thymoma, thymic carcinoma, and thymic neuroendocrine tumors (NETTs).
  • History of interstitial lung disease or pneumonia requiring oral or intravenous corticosteroids within the past year; use of vancomycin within the past month.
  • Ongoing chronic systemic corticosteroid therapy (equivalent to or greater than prednisone >10mg per day) or any other immunosuppressive therapy. Patients received inhale or topical corticosteroid are allowed.
  • Uncontrolled cardiac conditions, such as:
  • Heart failure with New York Heart Association (NYHA) classification ≥ Class II;
  • Unstable angina;
  • History of myocardial infarction within the past year;
  • Supraventricular or ventricular arrhythmias requiring treatment or intervention
  • Pregnant or breastfeeding women (pregnancy testing should be considered for women of childbearing potential with active sexual life)
  • History or presence of other malignancies, except for adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix, and papillary thyroid carcinoma.
  • Known hypersensitivity to macromolecule protein products or any component of QL1706.
  • Active infections requiring systemic treatment within 1 week prior to enrollment.
  • Administration of live vaccines within 30 days prior to the first dose of epalurilimab-tovorolimab.
  • History of organ transplantation or hematopoietic stem cell transplantation.
  • Any other condition assessed by the investigator as potentially compromising patient safety or compliance, such as severe illnesses requiring urgent treatment (including psychiatric disorders), significantly abnormal laboratory values, or other psychological, familial, or social risk factors.

Quoted from ClinicalTrials.gov, NCT06749899, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06749899, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06749899